People spend about a third of their lives asleep. When we get too little shut-eye, it takes a toll on attention, learning and memory, not to mention our physical health. Virtually all animals with complex brains seem to have this same need for sleep. But exactly what is it about sleep that’s so essential?
Can exercise slow or prevent cognitive decline in older people at increased risk for Alzheimer’s disease?
The new NIA-supported EXERT study, in partnership with the YMCA, is looking to find the right dose of exercise to slow memory loss.
These concepts were approved at the National Advisory Council on Aging (NACA) meeting on January 18, 2017. We have posted the approved concepts here to give interested researchers maximal lead time to plan projects.
Only the Beginning: Read about a new milestone in AD research as the Brain Health Registry surpasses the 50,000 participant mark.
We are thrilled to begin the New Year with over 50,000 participants in Brain Health Registry! We are grateful for your help in achieving this significant milestone, and cannot thank you enough for your efforts to help scientists better understand brain disease.
Read a great synopsis of 2016 AD research developments in the Alzheimer’s Forum’s—A Year in Research by Tom Fagan and Gabrielle Strobel
No use soft-pedaling a hard truth: The year ended on a downer. Solanezumab—the therapeutic antibody in line to be the first approved AD drug in well over a decade—failed to significantly slow cognitive decline in people with mild AD and a positive amyloid scan/CSF Aβ profile.
Concerns over the Zika virus have focused on pregnant women due to mounting evidence that is causes brain abnormalities in developing fetuses. However, new research in mice suggests that certain adult brain cells may be vulnerable to infection as well.
The NIA’s Bypass Budget Proposal for Fiscal Year 2018—Stopping Alzheimer’s Disease and Related Dementias: Advancing Our Nation’s Research Agenda is now available
At the direction of Congress, the National Institutes of Health (NIH) develops an annual professional judgment budget to estimate the funds needed to fully pursue scientific opportunities to meet the research goal of the Plan—to effectively treat and prevent Alzheimer’s and related dementias by 2025.
Researchers presenting at the Alzheimer’s Association International Conference 2016 (AAIC 2016) in Toronto introduced and described a new condition or patient status, known as Mild Behavioral Impairment (MBI), that may be a forerunner of neurodegeneration and progression to mild cognitive impairment (MCI) or dementia.
Today the Senate Committee on Appropriations approved a bill that would boost U.S. government funding for Alzheimer’s disease to almost $1.4 billion in fiscal year 2017.